NSG 533 – ADVANCED PHARMACOLOGY EXAM 300
COMPLETE QUESTIONS WITH CORRECT VERIFIED
ANSWERS AND DETAILED RATIONALE LATEST 2026-2027
ASSURED PASS!!!!!!!!!!!!!!!
The NSG 533 Advanced Pharmacology exam at Wilkes University is a
comprehensive, graduate-level assessment designed for nurse practitioner
students. It rigorously evaluates the ability to apply pharmacokinetic and
pharmacodynamic principles to clinical decision-making. The examination
emphasizes safe prescribing practices, including drug selection, dosing
adjustments for special populations, monitoring for adverse effects, and
managing complex drug interactions. Students must demonstrate mastery of
pharmacotherapeutics across diverse body systems, integrating evidence-
based guidelines with patient-specific factors such as genetics, age, and
comorbidities to optimize therapeutic outcomes and minimize patient harm.
1. A drug has a volume of distribution (Vd) of 500 L and a clearance (CL) of 50
L/hr. Which of the following best describes the expected half-life (t½) and clinical
implication of such a large Vd?
A) t½ = 5 hours; the drug is primarily confined to the vascular compartment.
B) t½ = 10 hours; the drug is likely highly protein-bound and restricted to plasma.
C) t½ = 7 hours; a loading dose may be required to achieve therapeutic
concentrations rapidly.
D) t½ = 6.93 hours; the drug is extensively distributed into tissues, possibly
sequestered in fat or bone.
Answer: D
Rationale: Half-life is calculated as t½ = 0.693 × Vd / CL = 0.693 × =
6.93 hours. A Vd of 500 L far exceeds total body water, indicating extensive tissue
distribution. This necessitates a loading dose to saturate tissue compartments and
achieve effective plasma concentrations. Option A describes a drug confined to
plasma (Vd ~3-5 L). Option B's t½ is incorrect; high protein binding typically
restricts Vd. Option C's t½ is incorrect.
2. A drug follows Michaelis-Menten elimination kinetics at therapeutic doses.
Which statement accurately describes the clinical consequence of this
pharmacokinetic property?
A) The half-life remains constant regardless of dose changes.
,B) Clearance is directly proportional to plasma concentration.
C) Small increases in dose can lead to disproportionate increases in plasma
concentration and toxicity.
D) The drug will be eliminated faster at higher concentrations.
Answer: C
Rationale: Michaelis-Menten (saturable) kinetics means that as concentration
approaches the maximum velocity (Vmax), the elimination pathways become
saturated. A minor dose increment can push the drug into the zero-order zone,
causing a steep, nonlinear rise in plasma levels. Option A describes first-order
kinetics. Option B is incorrect because clearance decreases as concentration rises.
Option D is opposite of the actual effect.
3. A 72-year-old patient with heart failure and reduced renal function is started on
digoxin. Which pharmacokinetic change in the elderly most directly increases the
risk of digoxin toxicity in this patient?
A) Increased hepatic first-pass metabolism.
B) Increased volume of distribution due to higher muscle mass.
C) Decreased glomerular filtration rate reducing renal clearance.
D) Increased intestinal motility enhancing absorption.
Answer: C
Rationale: Digoxin is primarily eliminated renally. In elderly patients, age-related
decline in glomerular filtration rate reduces clearance, prolonging the half-life and
increasing steady-state concentrations. Hepatic metabolism of digoxin is minimal.
Volume of distribution for digoxin decreases with age due to reduced muscle mass.
Intestinal motility decreases with age, not increases.
4. A patient on warfarin is started on amiodarone. The international normalized
ratio (INR) rises from 2.5 to 4.8 within 72 hours. This interaction is best explained
by which mechanism?
A) Amiodarone displaces warfarin from plasma albumin, increasing free warfarin.
B) Amiodarone inhibits CYP2C9, reducing warfarin metabolism.
C) Amiodarone induces CYP3A4, increasing warfarin clearance.
D) Amiodarone reduces platelet aggregation, potentiating warfarin's anticoagulant
effect.
Answer: B
Rationale: Warfarin is a racemic mixture; the S-enantiomer is metabolized by
CYP2C9. Amiodarone is a potent inhibitor of CYP2C9, decreasing warfarin
metabolism and significantly raising INR. Protein displacement is a minor and
transient mechanism. CYP3A4 induction would reduce warfarin levels.
,Amiodarone does not directly affect platelet aggregation in a manner that explains
this degree of INR elevation.
5. Which genetic polymorphism has the most significant clinical impact on the
metabolism of codeine, potentially leading to life-threatening toxicity in a rapid
metabolizer?
A) CYP2D6 ultra-rapid metabolizer phenotype.
B) CYP3A4 poor metabolizer phenotype.
C) CYP1A2 rapid metabolizer phenotype.
D) N-acetyltransferase slow acetylator phenotype.
Answer: A
Rationale: Codeine is a prodrug that requires O-demethylation by CYP2D6 to form
morphine, the active analgesic. Ultra-rapid metabolizers convert codeine to
morphine at an accelerated rate, resulting in high plasma morphine levels,
respiratory depression, and toxicity. CYP3A4, CYP1A2, and NAT polymorphisms
do not primarily govern this bioactivation step.
6. A patient with a history of peptic ulcer disease requires chronic nonsteroidal
anti-inflammatory drug (NSAID) therapy for osteoarthritis. Which of the following
strategies most effectively reduces the risk of gastrointestinal complications while
maintaining analgesia?
A) Add a proton pump inhibitor to a nonselective NSAID.
B) Switch to a COX-2 selective inhibitor without any gastroprotective agent.
C) Use a nonselective NSAID with a histamine-2 receptor antagonist.
D) Administer the NSAID enteric-coated with an antacid.
Answer: A
Rationale: The combination of a nonselective NSAID with a proton pump inhibitor
(PPI) has been shown to reduce the risk of gastric and duodenal ulcers comparably
to COX-2 inhibitors, while PPIs provide superior mucosal protection compared to
H2 antagonists alone. COX-2 inhibitors still carry a risk, especially without
protection. Enteric coating reduces local gastric irritation but does not prevent
systemic prostaglandin inhibition.
7. A patient is prescribed digoxin for atrial fibrillation with rapid ventricular
response. Which electrolyte disturbance most predisposes this patient to digoxin-
induced cardiac arrhythmias?
A) Hyperkalemia.
B) Hypermagnesemia.
C) Hypokalemia.
D) Hypercalcemia.
, Answer: C
Rationale: Hypokalemia increases the binding of digoxin to the sodium-potassium-
ATPase pump, enhancing its toxic effects and predisposing to arrhythmias.
Hyperkalemia actually reduces digoxin binding. Hypermagnesemia is not a
primary risk factor. Hypercalcemia can increase the risk of digoxin toxicity but
hypokalemia is the most clinically significant and common disturbance.
8. The nurse practitioner is managing a patient on phenytoin for a seizure disorder.
The patient's albumin level drops from 4.0 g/dL to 2.5 g/dL. The patient's total
phenytoin level is reported as 8 mcg/mL. Which of the following actions is most
appropriate?
A) Increase the phenytoin dose immediately because the level is subtherapeutic.
B) Calculate the corrected phenytoin level and interpret that the free drug
concentration may be therapeutic.
C) Discontinue phenytoin due to toxicity because total levels are low.
D) Add valproic acid to displace phenytoin from proteins and increase efficacy.
Answer: B
Rationale: Phenytoin is highly protein-bound (approximately 90%). In
hypoalbuminemia, the free (active) fraction increases even if the total
concentration appears low. A corrected phenytoin level should be calculated using
the formula: corrected total = measured total / [(0.2 × albumin) + 0.1] or using
standard correction nomograms. Option A would lead to toxicity. Option C is
incorrect. Option D would further increase free phenytoin and risk toxicity.
9. A patient on lithium therapy develops nausea, vomiting, coarse tremor, and
confusion. The serum lithium level is 2.2 mEq/L. Which of the following
treatments is the initial priority?
A) Administer activated charcoal.
B) Discontinue lithium and provide intravenous normal saline.
C) Start hemodialysis immediately.
D) Administer sodium polystyrene sulfonate.
Answer: B
Rationale: Lithium toxicity at 2.2 mEq/L (moderate to severe) requires immediate
discontinuation of the drug and aggressive hydration with normal saline to enhance
renal clearance. Activated charcoal does not bind lithium. Hemodialysis is reserved
for severe toxicity (levels > 3.5-4.0 mEq/L) or renal failure. Sodium polystyrene
sulfonate is not a primary treatment for acute lithium poisoning.
COMPLETE QUESTIONS WITH CORRECT VERIFIED
ANSWERS AND DETAILED RATIONALE LATEST 2026-2027
ASSURED PASS!!!!!!!!!!!!!!!
The NSG 533 Advanced Pharmacology exam at Wilkes University is a
comprehensive, graduate-level assessment designed for nurse practitioner
students. It rigorously evaluates the ability to apply pharmacokinetic and
pharmacodynamic principles to clinical decision-making. The examination
emphasizes safe prescribing practices, including drug selection, dosing
adjustments for special populations, monitoring for adverse effects, and
managing complex drug interactions. Students must demonstrate mastery of
pharmacotherapeutics across diverse body systems, integrating evidence-
based guidelines with patient-specific factors such as genetics, age, and
comorbidities to optimize therapeutic outcomes and minimize patient harm.
1. A drug has a volume of distribution (Vd) of 500 L and a clearance (CL) of 50
L/hr. Which of the following best describes the expected half-life (t½) and clinical
implication of such a large Vd?
A) t½ = 5 hours; the drug is primarily confined to the vascular compartment.
B) t½ = 10 hours; the drug is likely highly protein-bound and restricted to plasma.
C) t½ = 7 hours; a loading dose may be required to achieve therapeutic
concentrations rapidly.
D) t½ = 6.93 hours; the drug is extensively distributed into tissues, possibly
sequestered in fat or bone.
Answer: D
Rationale: Half-life is calculated as t½ = 0.693 × Vd / CL = 0.693 × =
6.93 hours. A Vd of 500 L far exceeds total body water, indicating extensive tissue
distribution. This necessitates a loading dose to saturate tissue compartments and
achieve effective plasma concentrations. Option A describes a drug confined to
plasma (Vd ~3-5 L). Option B's t½ is incorrect; high protein binding typically
restricts Vd. Option C's t½ is incorrect.
2. A drug follows Michaelis-Menten elimination kinetics at therapeutic doses.
Which statement accurately describes the clinical consequence of this
pharmacokinetic property?
A) The half-life remains constant regardless of dose changes.
,B) Clearance is directly proportional to plasma concentration.
C) Small increases in dose can lead to disproportionate increases in plasma
concentration and toxicity.
D) The drug will be eliminated faster at higher concentrations.
Answer: C
Rationale: Michaelis-Menten (saturable) kinetics means that as concentration
approaches the maximum velocity (Vmax), the elimination pathways become
saturated. A minor dose increment can push the drug into the zero-order zone,
causing a steep, nonlinear rise in plasma levels. Option A describes first-order
kinetics. Option B is incorrect because clearance decreases as concentration rises.
Option D is opposite of the actual effect.
3. A 72-year-old patient with heart failure and reduced renal function is started on
digoxin. Which pharmacokinetic change in the elderly most directly increases the
risk of digoxin toxicity in this patient?
A) Increased hepatic first-pass metabolism.
B) Increased volume of distribution due to higher muscle mass.
C) Decreased glomerular filtration rate reducing renal clearance.
D) Increased intestinal motility enhancing absorption.
Answer: C
Rationale: Digoxin is primarily eliminated renally. In elderly patients, age-related
decline in glomerular filtration rate reduces clearance, prolonging the half-life and
increasing steady-state concentrations. Hepatic metabolism of digoxin is minimal.
Volume of distribution for digoxin decreases with age due to reduced muscle mass.
Intestinal motility decreases with age, not increases.
4. A patient on warfarin is started on amiodarone. The international normalized
ratio (INR) rises from 2.5 to 4.8 within 72 hours. This interaction is best explained
by which mechanism?
A) Amiodarone displaces warfarin from plasma albumin, increasing free warfarin.
B) Amiodarone inhibits CYP2C9, reducing warfarin metabolism.
C) Amiodarone induces CYP3A4, increasing warfarin clearance.
D) Amiodarone reduces platelet aggregation, potentiating warfarin's anticoagulant
effect.
Answer: B
Rationale: Warfarin is a racemic mixture; the S-enantiomer is metabolized by
CYP2C9. Amiodarone is a potent inhibitor of CYP2C9, decreasing warfarin
metabolism and significantly raising INR. Protein displacement is a minor and
transient mechanism. CYP3A4 induction would reduce warfarin levels.
,Amiodarone does not directly affect platelet aggregation in a manner that explains
this degree of INR elevation.
5. Which genetic polymorphism has the most significant clinical impact on the
metabolism of codeine, potentially leading to life-threatening toxicity in a rapid
metabolizer?
A) CYP2D6 ultra-rapid metabolizer phenotype.
B) CYP3A4 poor metabolizer phenotype.
C) CYP1A2 rapid metabolizer phenotype.
D) N-acetyltransferase slow acetylator phenotype.
Answer: A
Rationale: Codeine is a prodrug that requires O-demethylation by CYP2D6 to form
morphine, the active analgesic. Ultra-rapid metabolizers convert codeine to
morphine at an accelerated rate, resulting in high plasma morphine levels,
respiratory depression, and toxicity. CYP3A4, CYP1A2, and NAT polymorphisms
do not primarily govern this bioactivation step.
6. A patient with a history of peptic ulcer disease requires chronic nonsteroidal
anti-inflammatory drug (NSAID) therapy for osteoarthritis. Which of the following
strategies most effectively reduces the risk of gastrointestinal complications while
maintaining analgesia?
A) Add a proton pump inhibitor to a nonselective NSAID.
B) Switch to a COX-2 selective inhibitor without any gastroprotective agent.
C) Use a nonselective NSAID with a histamine-2 receptor antagonist.
D) Administer the NSAID enteric-coated with an antacid.
Answer: A
Rationale: The combination of a nonselective NSAID with a proton pump inhibitor
(PPI) has been shown to reduce the risk of gastric and duodenal ulcers comparably
to COX-2 inhibitors, while PPIs provide superior mucosal protection compared to
H2 antagonists alone. COX-2 inhibitors still carry a risk, especially without
protection. Enteric coating reduces local gastric irritation but does not prevent
systemic prostaglandin inhibition.
7. A patient is prescribed digoxin for atrial fibrillation with rapid ventricular
response. Which electrolyte disturbance most predisposes this patient to digoxin-
induced cardiac arrhythmias?
A) Hyperkalemia.
B) Hypermagnesemia.
C) Hypokalemia.
D) Hypercalcemia.
, Answer: C
Rationale: Hypokalemia increases the binding of digoxin to the sodium-potassium-
ATPase pump, enhancing its toxic effects and predisposing to arrhythmias.
Hyperkalemia actually reduces digoxin binding. Hypermagnesemia is not a
primary risk factor. Hypercalcemia can increase the risk of digoxin toxicity but
hypokalemia is the most clinically significant and common disturbance.
8. The nurse practitioner is managing a patient on phenytoin for a seizure disorder.
The patient's albumin level drops from 4.0 g/dL to 2.5 g/dL. The patient's total
phenytoin level is reported as 8 mcg/mL. Which of the following actions is most
appropriate?
A) Increase the phenytoin dose immediately because the level is subtherapeutic.
B) Calculate the corrected phenytoin level and interpret that the free drug
concentration may be therapeutic.
C) Discontinue phenytoin due to toxicity because total levels are low.
D) Add valproic acid to displace phenytoin from proteins and increase efficacy.
Answer: B
Rationale: Phenytoin is highly protein-bound (approximately 90%). In
hypoalbuminemia, the free (active) fraction increases even if the total
concentration appears low. A corrected phenytoin level should be calculated using
the formula: corrected total = measured total / [(0.2 × albumin) + 0.1] or using
standard correction nomograms. Option A would lead to toxicity. Option C is
incorrect. Option D would further increase free phenytoin and risk toxicity.
9. A patient on lithium therapy develops nausea, vomiting, coarse tremor, and
confusion. The serum lithium level is 2.2 mEq/L. Which of the following
treatments is the initial priority?
A) Administer activated charcoal.
B) Discontinue lithium and provide intravenous normal saline.
C) Start hemodialysis immediately.
D) Administer sodium polystyrene sulfonate.
Answer: B
Rationale: Lithium toxicity at 2.2 mEq/L (moderate to severe) requires immediate
discontinuation of the drug and aggressive hydration with normal saline to enhance
renal clearance. Activated charcoal does not bind lithium. Hemodialysis is reserved
for severe toxicity (levels > 3.5-4.0 mEq/L) or renal failure. Sodium polystyrene
sulfonate is not a primary treatment for acute lithium poisoning.
